Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition. An ideal source for hematologists, oncologists, and cancer researchers, this Second Edition features: ULLIa new eight-page color insert/LILI200 color and black-and-white illustrations/LILIreworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy/LILIthoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field/LI/ULNew topics in Myelodysplastic Syndrome include: ULLIdel(5q) and 5q-syndrome, CMML, and MDS-MPD overlap syndrome/LILIthe reborn DNA methyltransferase inhibiting nucleoside analogs/LILIthe diagnosis of chronic myelomonocytic leukemia and other MDS cases with myeloproliferative features/LILIthe role of mitochondria and the potential importance of iron overload in MDS/LILIglobal genomics approaches, such as cDNA expression arrays, array-based comparative genomic hybridization, and single nucleotide polymorphism array/LILIthe role of abnormal mitochondrial ferritin accumulation and other mitochondrial metabolic anomalies in MD/LILIother disease-associated alterations, such as abnormalities of B lymphocyte populations in MD/LILIthree recently approved drugs: azacitidine, lenalidomide, and decitabine/LI/UL